• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

Professional Introduction to 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride (CAS No. 1156884-70-6)

1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride, a compound with the CAS number 1156884-70-6, represents a significant advancement in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of imidazole derivatives, which have garnered considerable attention due to their diverse biological activities and potential therapeutic applications. The structural motif of this molecule, featuring a 4-methyl-1H-imidazol-2-yl substituent linked to an ethylamine group, endows it with unique chemical and pharmacological properties that make it a promising candidate for further investigation.

The dihydrochloride salt form of this compound enhances its solubility in aqueous solutions, facilitating its use in various biochemical assays and in vitro studies. This property is particularly crucial for drug development, where solubility often dictates the bioavailability and efficacy of a potential therapeutic agent. The imidazole ring in 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride is known for its ability to interact with biological targets such as enzymes and receptors, making it a versatile scaffold for designing molecules with specific pharmacological effects.

In recent years, there has been growing interest in imidazole derivatives due to their role as intermediates in the synthesis of various pharmaceuticals. The 4-methyl-1H-imidazol-2-yl moiety is particularly noteworthy because it can be modified in multiple ways to produce analogs with tailored biological activities. For instance, studies have shown that derivatives of this type can exhibit antimicrobial, anti-inflammatory, and even anticancer properties. These findings have spurred further research into understanding the mechanisms by which these compounds exert their effects on biological systems.

The pharmaceutical industry has been actively exploring new drug candidates derived from imidazole scaffolds, recognizing their potential to address unmet medical needs. 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride is being investigated as a precursor for more complex molecules designed to interact with specific biological pathways. Its structural features make it a valuable building block for drug discovery efforts aimed at developing novel treatments for a range of diseases.

One of the most exciting areas of research involving 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride is its potential application in the treatment of neurological disorders. Imidazole derivatives have shown promise in modulating neurotransmitter systems, which could make them effective against conditions such as depression, anxiety, and neurodegenerative diseases. Preliminary studies suggest that this compound may interact with serotonin receptors, potentially leading to therapeutic benefits similar to those observed with selective serotonin reuptake inhibitors (SSRIs).

The synthesis of 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic techniques, including catalytic hydrogenation and nucleophilic substitution reactions, are employed to construct the desired molecular framework. The introduction of the hydrochloride salt form is achieved through quaternization followed by salt formation, which not only improves solubility but also enhances stability during storage and transport.

The pharmacokinetic properties of this compound are also under investigation. Understanding how 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride is absorbed, distributed, metabolized, and excreted (ADME) is crucial for determining its suitability as a drug candidate. Preliminary pharmacokinetic studies indicate that the compound exhibits reasonable bioavailability and moderate metabolic clearance rates, suggesting that it may have a favorable pharmacokinetic profile for therapeutic use.

In conclusion, 1-(4-Methyl-1H-imidazol-2-yl)ethylamine dihydrochloride (CAS No. 1156884-70-6) represents a significant advancement in pharmaceutical chemistry with potential applications across multiple therapeutic areas. Its unique structural features and promising biological activities make it an attractive candidate for further research and development. As our understanding of its pharmacological properties continues to grow, this compound is poised to play a crucial role in the discovery and development of new treatments for human diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)